Blueclinical Investigacao E Desenvolvimento Em Saude Lda. — Clinical Trial Site

86 Registered trials

2 Currently recruiting

Organisation

Blueclinical Investigacao E Desenvolvimento Em Saude Lda.

Location

Porto, Portugal

Identifier

ORG-100011139

Address

Rua De Sarmento De Beires 153 0 Floor 3rd Floor, 4250-449, Portugal

Departments

Allergy and Clinical Inmunology
BlueClinical Phase I
Med
Medical Management

Clinical trials at this site (86)

Search interface

Investigate Drug-Drug Interactions between LVDS (Levonorgestrel Vaginal Delivery System) and Tampons and Lubricants in Healthy Female Partic… Ended

2025-520517-32-00 No medical condition. 3 2025-05-29
Investigation of Drug-Drug Interactions between LVDS (Levonorgestrel Vaginal Delivery System) and Miconazole in Healthy Female Participants. Ended

2025-520516-33-00 No medical condition. 3 2025-05-28
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant… Ended

2024-519250-37-00 No medical condition. 2 2025-05-27
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® M… Ended

2024-519640-32-00 No medical condicion. 2 2025-04-22
Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227 Ended

2024-518734-87-00 No medical condition. 3 2025-03-25
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions Ended

2025-520716-34-00 No medical condition. 2 2025-03-17
Bioequivalence of Lisdexamfetamine dimesylate 70 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-516826-79-00 No medical condition. 2 2025-03-10
Bioequivalence of Lisdexamfetamine dimesylate 20 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-516827-14-00 No medical condition. 2 2025-03-10
Drug-Drug Interaction between Empagliflozin 25 mg Film-Coated Tablets and Alogliptin 25 mg Film-Coated Tablets in Healthy Participants Under… Ended

2025-520459-10-00 No medical condition. 3 2025-02-18
Drug-Drug Interaction between Alogliptin 25 mg Film-Coated Tablets and Empagliflozin 25 mg Film-Coated Tablets in Healthy Participants Under… Ended

2025-520460-18-00 No medical condition. 3 2025-02-18
Bioequivalence of Calcifediol monohydrate 0.266 mg Soft Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-513480-37-00 No medical condition. 2 2025-01-28
Bioequivalence of Metamizole Sodium 500 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2024-514447-29-00 No medical condition. 2 2024-12-02
Bioequivalence of Lisdexamfetamine dimesylate 10 mg/mL Oral Solution in Healthy Participants Under Fasting Conditions. Ended

2024-516828-33-00 No medical condition. 2 2024-11-15
Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects. Ended

2024-516854-23-00 No medical condition. 1 2024-11-11
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions. Ended

2024-515947-49-00 No medical condition. 2 2024-10-07
Bioequivalence of Linagliptin 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended

2024-516400-42-00 No medical condition. 2 2024-10-02
Pharmacokinetics and the Effect of Food on the Pharmacokinetics of TW102 in Healthy Subjects. Ended

2024-510936-31-00 No medical condition. 3 2024-10-01
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended

2024-511647-25-00 No medical condition. 2 2024-09-24
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512908-19-00 No medical condition. 2 2024-09-09
Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (Hig… Ended

2024-514298-23-00 No medical condicion. 3 2024-09-02
Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers. Ended

2023-508439-30-00 Multiple Sclerosis 3 2024-08-21
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL… Ended

2024-513753-75-00 No medical condition. 2 2024-08-12
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-514448-10-00 No medical condition. 2 2024-08-09
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended

2024-513752-15-00 No medical condition. 2 2024-08-01